Author

Wendi Malley

Observed names: Malley, Wendi, W. Malley

Observed institutions: Amgen (United States), The University of Texas MD Anderson Cancer Center, University of Massachusetts Chan Medical School, University of Washington, University of Rochester Medicine, University of California San Diego, NYU Langone Health, Swedish Medical Center, Southbury Clinic, Instituto Biofisika, New York University

OpenAlex ID: A5073730210

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data

2020 · Philip Mease, Christina Charles-Schoeman, et al. · Annals of the Rheumatic Diseases · 218

Clinical Characteristics, Disease Activity, and Patient‐Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

2017 · Philip J. Mease, Chitra Karki, et al. · Arthritis Care & Research · 125

Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry

2017 · Leslie R. Harrold, Bradley S. Stolshek, et al. · Clinical Rheumatology · 55

Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry

2017 · Philip J. Mease, Chitra Karki, et al. · The Journal of Rheumatology · 27

Assessing clusters of comorbidities in rheumatoid arthritis: a machine learning approach

2023 · Daniel H. Solomon, Hongshu Guan, et al. · Arthritis Research & Therapy · 14

Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease Activity

2017 · Leslie R. Harrold, Bradley S. Stolshek, et al. · The Journal of Rheumatology · 10

Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

2022 · Philip J. Mease, Alexis Ogdie, et al. · Drugs - Real World Outcomes · 8

Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas’ Psoriasis Registry

2021 · Jessica A. Walsh, Kristina Callis Duffin, et al. · Dermatology and Therapy · 6

65063 Characterization of treatment, disease burden, and patient-reported outcome measures in a real-world cohort of patients with alopecia areata: the CorEvitas Alopecia Areata Registry

2025 · Maryanne Senna, Brittany Craiglow, et al. · Journal of the American Academy of Dermatology

Observed differences in characteristics of secondary-progressive multiple sclerosis and relapsing-remitting multiple sclerosis patients in the US-based Corrona MS Registry (1300)

2020 · Daniel Kantor, Bruce Bebo, et al. · Neurology

Demographic, clinical and patient-reported characteristics of patients on ocrelizumab versus other disease-modifying therapies in the Corrona Multiple Sclerosis Registry (2915)

2020 · Daniel Kantor, Natalie J. Engmann, et al. · Neurology

AB0743 Characterization of Psoriatic Arthritis Patients by Skin and Joint Severity: Results from The Corrona Spondyloarthritis Registry

2016 · P.J. Mease, M. Skup, et al. · Annals of the Rheumatic Diseases

THU0433 Persistency with TNFI in Biologic Experienced versus Biologic Native PSA Patients Enrolled in Corrona Registry

2016 · C.J. Etzel, B. Stolshek, et al. · Annals of the Rheumatic Diseases

THU0423 Time To Rebound in Joint Symptoms Following Discontinuation of TNFI Therapy after Achieving Low Disease Activity or Remission in Psoriatic Arthritis Patients Enrolled in The US Corrona Registry

2016 · L.R. Harrold, B. Stolshek, et al. · Annals of the Rheumatic Diseases

Works count: 16

Citation count: 463

H-index: 7

I10-index: 6